Witliv Tablet contains Ursodeoxycholic Acid 300 mg, a hydrophilic bile acid used primarily in the treatment of cholestatic liver diseases. Ursodeoxycholic Acid acts by reducing the cholesterol content of bile and bile stones and by stimulating bile flow, thereby improving liver function and preventing the progression of liver damage. It is commonly prescribed for conditions such as primary biliary cholangitis, intrahepatic cholestasis, and to dissolve certain types of cholesterol gallstones in patients who are unsuitable for surgery. Witliv Tablet is also utilized as an adjunct therapy in various hepatic disorders to enhance bile secretion and protect hepatocytes from toxic bile acids. The mechanism involves alteration of the bile acid pool composition, reduction of cytotoxicity, and immunomodulatory effects that contribute to the stabilization of liver function tests and improvement of clinical symptoms. Dosage and duration of treatment with Witliv Tablet should be individualized based on the specific condition and patient response, under medical supervision. Common adverse effects are generally mild and may include gastrointestinal discomfort, diarrhea, and rarely, allergic reactions. Regular monitoring of liver function tests is recommended during therapy to assess efficacy and detect potential adverse effects. Witliv Tablet should be used cautiously in patients with advanced liver disease or hypersensitivity to Ursodeoxycholic Acid.